CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non-Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom
{{output}}
Aims: The aim of this study was to describe the clinical outcomes, demographics, and clinical characteristics of patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) treated with durvalumab a... ...
